Morgan Stanley analyst Terence Flynn raised Bristol Myers’ price target to $40 from $37, maintaining an Underweight rating. 2026 revenue and EPS guidance exceeded expectations, driven by higher Eliquis guidance. Stay informed with the latest news and analysis to maximize your portfolio’s potential. Trump Trade: Argentina announces U.S. will reduce hundreds of tariffs. Bristol Myers’ price target raised to $68 from $64 at BofA, to $72 from $62 at Guggenheim, to $64 from $60 at Citi, and to $60 from $55 at Wells Fargo.

Read more at Yahoo Finance: Bristol Myers price target raised to $40 from $37 at Morgan Stanley